Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

“Using stevioside to enhance minoxidil delivery represents a promising step toward more effective and natural treatments for ...

Women using menopausal hormone therapy have up to a 30% lower risk of developing esophageal and gastric cancers, with the ...

A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in ...

The future of high streets lies in making them true destinations, blending retail, leisure, hospitality and culture” – Chris ...

David A. Shargel of Bracewell LLP discusses the potential risks of using AI tools in the discovery process and what lawyers ...

The slowdown in system starts is not due to any issues with the new system. However, it is a situation where many customers ...

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...

Colorado and over 20 other states have banned the practice aimed at changing the sexual orientation or gender identity of ...

The Health Secretary's affinity for saturated fat and his ire over ultra-processed foods could influence federal food ...

Jake Gabell was sworn in Wednesday as the city’s new planning and zoning administrator, replacing longtime city planner Bryan ...